MML Investors Services LLC Buys 28,130 Shares of AbbVie Inc. $ABBV

Key Points

• MML Investors Services LLC increased its AbbVie stake by 4.5% in the fourth quarter, buying 28,130 additional shares and bringing its total holdings to 659,523 shares valued at about $150.7 million.
• Several other institutional investors also added to AbbVie, and institutions now own 70.23% of the company’s stock, highlighting continued Wall Street interest in the name.
• Analysts remain generally constructive on AbbVie, with an average rating of Moderate Buy and a consensus price target of $253.43; recent coverage included a DZ Bank upgrade to Strong Buy.

MML Investors Services LLC grew its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 4.5% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 659,523 shares of the company's stock after buying an additional 28,130 shares during the quarter. MML Investors Services LLC's holdings in AbbVie were worth $150,694,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. increased its position in AbbVie by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company's stock valued at $41,155,601,000 after acquiring an additional 448,554 shares during the period. Thornburg Investment Management Inc. increased its position in AbbVie by 25.5% in the 3rd quarter. Thornburg Investment Management Inc. now owns 401,760 shares of the company's stock valued at $93,024,000 after acquiring an additional 81,625 shares during the period. Channing Capital Management LLC increased its position in AbbVie by 10.5% in the 3rd quarter. Channing Capital Management LLC now owns 55,647 shares of the company's stock valued at $12,885,000 after acquiring an additional 5,302 shares during the period. Procyon Advisors LLC increased its position in AbbVie by 19.9% in the 4th quarter. Procyon Advisors LLC now owns 32,752 shares of the company's stock valued at $7,484,000 after acquiring an additional 5,427 shares during the period. Finally, Woodley Farra Manion Portfolio Management Inc. increased its position in AbbVie by 358.1% in the 3rd quarter. Woodley Farra Manion Portfolio Management Inc. now owns 14,746 shares of the company's stock valued at $3,414,000 after acquiring an additional 11,527 shares during the period. Institutional investors own 70.23% of the company's stock.

Analysts Set New Price Targets

ABBV has been the subject of several recent analyst reports. DZ Bank upgraded shares of AbbVie from a "hold" rating to a "strong-buy" rating in a research report on Thursday, April 30th. Piper Sandler increased their price objective on shares of AbbVie from $294.00 to $298.00 and gave the stock an "overweight" rating in a research report on Thursday, May 14th. William Blair reiterated an "outperform" rating on shares of AbbVie in a research report on Monday, March 9th. Cantor Fitzgerald reiterated an "overweight" rating and set a $240.00 price objective on shares of AbbVie in a research report on Thursday, April 30th. Finally, Evercore set a $235.00 price objective on shares of AbbVie in a research report on Friday, May 15th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $253.43.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie said nine-year CLL14 data showed venetoclax plus obinutuzumab delivered durable progression-free survival in previously untreated chronic lymphocytic leukemia, strengthening the case for the drug’s long-term commercial value. AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
• Positive Sentiment: Investors are also focused on AbbVie’s broader pipeline and franchise strength, with commentary pointing to Skyrizi and Rinvoq continuing to drive revenue growth, which supports the company’s outlook beyond legacy Humira. Will Skyrizi & Rinvoq Continue to Drive AbbVie's Topline Through 2026?
• Neutral Sentiment: Several market commentaries described AbbVie as a defensive, high-quality compounder, but noted the shares may not be cheap at current levels, which suggests valuation may temper upside even with strong fundamentals. AbbVie: A Defensive Compounder Worth Holding, But Not A Bargain Buy
• Negative Sentiment: One article highlighted regulatory risk around AbbVie’s fast-acting neurotoxin TrenibotE after an FDA complete response letter, which could delay a potential growth driver if development setbacks persist. FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

AbbVie Stock Down 0.1%

ABBV opened at $227.54 on Monday. AbbVie Inc. has a twelve month low of $181.73 and a twelve month high of $244.81. The company has a fifty day moving average of $211.05 and a 200-day moving average of $219.00. The stock has a market cap of $402.02 billion, a PE ratio of 112.09, a price-to-earnings-growth ratio of 0.70 and a beta of 0.32.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.06. The company had revenue of $15 billion during the quarter, compared to analysts' expectations of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. AbbVie's revenue for the quarter was up 12.4% compared to the same quarter last year. During the same period in the prior year, the company posted $2.46 earnings per share. Sell-side analysts anticipate that AbbVie Inc. will post 14.3 EPS for the current fiscal year.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.